Last term, the U.S. Supreme Court did something strange: the Court unanimously affirmed a circuit decision, which had unanimously affirmed a trial court decision. Little about the law seemed ripe for dispute or change, nevertheless, in Amgen v. Sanofi the Supreme Court spoke. Seven months later, innovators and patent practitioners are still scratching their heads. What impact, if any, does Amgen have? Is there a sign lower courts are interpreting Amgen as signaling a change in American patent law or did it merely ratify what already existed?
Recent Posts
- Other Barks and Bites for Friday, April 26: World Intellectual Property Day Celebrated Around the Globe; China Tops List for AI Patents Granted; EPO Releases Cleantech Study on World IP Day
- Celebrating World IP Day: Is the Innovative Future Sustainable?
- The Rise of IP Lawsuits When Posting Images: How to Navigate and Avoid Copyright Infringement Issues
- The SEP Couch: Lyse Brillouet on Managing SEPs and Open Standards
- Unveiling The Untapped Potential of Brazil’s Solar Energy Market